FIGURE 1: Ion currents determining the atrial action potential and the occurrence of each current in relation to the action potential, and agents which block each, are shown. Arrows pointing to the left and downward rectangles (beige) indicate inward currents: arrows pointing to the right and upward rectangles (blue) indicate outward currents.
INTRODUCTION
This year is the centenary of the fi rst ECG recording of atrial fi brillation (AF) by Hering, (1) but drug therapy for the condition was reported long before that in 1835 by Bouillaud. (2) Current drug therapy for AF includes drugs for ventricular rate control, anti-arrhythmic drugs for rhythm control, and anti-coagulants. The 3 essential problems of this arrhythmia are symptoms, thrombo-embolism, and tachycardia-induced cardiomyopathy. The prevention of tachycardia-induced cardiomyopathy requires rate control; the prevention of thrombo-embolism requires anti-coagulation; and the suppression of symptoms requires rate control in all patients and rhythm control in some. Those are patients who have symptoms despite rate control or in whom rhythm control is suspected to be a better strategy. Rhythm control is suspected to be a better strategy in younger patients, when symptoms are severe, in the presence of diastolic dysfunction in hypertension or hypertrophic cardiomyopathy, and in mitral stenosis.
RATE CONTROL
Current options for rate control include the well-known drugs digoxin, rate-slowing calcium channel blockers, viz. verapamil and diltiazem, beta-blockers, and amiodarone, and the "ablate and pace" procedure.
Digoxin, although historically the very fi rst drug used in this condition, is known to be rather ineffective, especially when exercise heart rates are evaluated, and there is also concern about increased mortality with digoxin in females with heart failure (Digoxin Investigation Group Trial) (3) especially if the serum level is > 1.2ng/ml, (4) and in both genders in the SPORTIF III and V trials in patients with AF. (5) Amiodarone, although effi cacious in ventricular rate control, is seldom used for this indication alone because of serious non-cardiac toxicity.
What are future options for rate control? Dronederone is an amiodarone congener which is non-iodinated and consequently has fewer side-effects, especially thyroid and pulmonary, and consequently may well have a place in the future rate control armamentarium. It has been shown to lower the ventricular rate by 12bpm at rest and 24bpm on exercise in the ERATO trial. (6) A number of adenosine agonists (8) stratify the risk for thrombo-embolism according to certain "major", "moderate" and "minor" risk factors (Table I) . Warfarin is recommended if any one major risk factor is present, or if two moderate risk factors are present, or if one moderate and a number of minor risk factors are present. Low-dose aspirin is recommended for the rest.
New options for anti-coagulation are listed in Table II . Clopidogrel as an alternative to aspirin is the subject of an ongoing trial namely ACTIVE A. Clopidogrel plus aspirin as an alternative to warfarin has proved to be inferior in the ACTIVE W trial. (9) Recently idraparinux in comparison to warfarin proved to be more effective at prevention of thrombo-embolism, but caused signifi cantly more bleeding (AMADEUS trial). 
RHYTHM CONTROL
Apart from radio-frequency ablation options for rhythm control (pulmonary veins, accessory pathway, and cavo-tricuspid isthmus for fl utter) in selected patients, the vast majority of patients with AF in whom the rhythm control strategy is being pursued, will require drug therapy. Currently in South Africa there are 4 drugs available for this purpose, viz. the 2 class IC drugs fl ecainide and propafenone, a betablocker with class III activity sotalol, and a multiple class action drug amiodarone. The clinical niches and usage of these drugs are discussed elsewhere and will not be elaborated on here. The 6 so-called "strategy trials", viz. PIAF, (12) STAF, (13) RACE, (14) AFFIRM, (15) HOT CAFÉ (16) and AF-CHF (17) concluded that rhythm control is not superior to rate control, so that it might well be questioned whether there is a point in new rhythm control drugs. It was however clear from a subsequent analysis of the largest of these trials, viz. AFFIRM that sinus rhythm was a very powerful predictor of survival (hazard ratio 0.54), but that this was offset by a powerful negative effect of the drugs used to control rhythm (hazard ratio 1.41). (18) Thus rhythm-controlling drugs without the adverse effects of the current generation are likely to have a survival benefi t.
Future options for rhythm control are listed in Table III analysis showed that ß-blockers in systolic heart failure resulted in a 27% risk reduction for new-onset AF. (19) To what extent this is a direct anti-arrhythmic effect versus an indirect effect on blood pressure, pump function and prevention of myocardial infarction, is not clear. ACEinhibitors were fi rst shown in a small Dutch study with lisinopril to have a benefi t in the maintenance of sinus rhythm after cardioversion; (20) subsequently in a large post-MI trial with trandolopril there was a benefi t in AF prevention; (21) and in a large heart failure trial with enalapril (SOLVD) there was a similar benefi t. (22) In the case of ARBs, in a secondary prevention trial, Madrid from Madrid showed that irbesartan combined with amiodarone was better at maintenance of sinus rhythm after cardioversion than amiodarone alone. (23) Subsequently primary prevention of AF has been shown in large trials in hypertension with losartan (LIFE), (24) and in heart failure with valsartan (VAL-HeFT) (25) and candesartan (CHARM).
(26) Recently a meta-analysis of prevention of AF with ACE-inhibitors and ARBs reported both to be effective provided that there was either LV hypertrophy or systolic dysfunction. (27) Statins have been mooted to have an anti-arrhythmic benefi t, particularly for atrial fi brillation, on the basis of experimental and observational clinical studies. This effect may be due to their antiinfl ammatory or anti-oxidant properties, and they are known to have effects on matrix metallo-proteinases, nitric oxide synthesis and L-type calcium currents which may also translate into anti-arrhythmic benefi t.
Earlier this year a meta-analysis of 6 studies and 3 557 patients showed a signifi cant benefi t, more marked in the 3 secondary prevention trials than in the 3 primary prevention trials (which were in patients having acute coronary syndrome or undergoing cardiac surgery).
The background to anti-infl ammatory therapy is that 66% of atrial biopsies in lone AF have myocarditis, and C-reactive protein (CRP) levels are raised in AF, more so in permanent AF than in persistent AF and least so in paroxysmal AF. The success of cardioversion has been related to CRP levels and thrombo-embolic risk correlates with CRP levels. A study has shown that treatment with methylprednisolone successfully prevents recurrence and the development of permanence in atrial fi brillation, and that this also correlated with reduction in CRP levels. (29) Atrial fi brosis in structural heart disease is an important substrate for AF. Anti-fi brosis therapy includes the aldosterone antagonists spironolactone and eplerenone, and a specifi c anti-fi brotic drug pirfenidone. In a dog study, pirfenidone has been shown to signifi cantly reduce vulnerability to AF and atrial remodeling. 
Dronedarone, like amiodarone, blocks I Kr , I Ks , I Ca-L , I to , I Na , I Kach , alpha and beta adrenergic receptors, but contains no iodine and, as a result, has fewer side-effects especially thyroid and pulmonary.
A number of clinical trials have been completed with this drug. DAFNE was a dose-ranging study comparing 400mg versus 600mg versus 800mg BD and showed that 600mg and 800mg were no more effective, but caused more side-effects. (32) ANDROMEDA was a trial in heart with dronedarone compared to 3.8% on placebo, due to worsening heart failure. It is thought that a rise in serum creatinine from a renal tubular effect of the drug led to discontinuation of ACE-I/ARB therapy by clinicians. (33) EURIDIS and ADONIS were identical trials conducted in Europe and America showing the effi cacy of dronedarone at the maintenance of sinus rhythm after cardioversion with signifi cant success (hazard ratio = 0.75 and P<0.001) after 1 year follow-up. (34) The oneyear recurrence rate on dronedarone was 65%, whereas it was only 25% with amiodarone in the Canadian trial of Atrial Fibrillation, (35) suggesting that it is not quite as effi cacious as amiodarone. In ATHENA, the biggest anti-arrhythmic drug trial to date with 4 628 patients, dronedarone was shown to signifi cantly reduce the primary endpoint, In dog experiments, rotigaptide reduces vulnerability to AF in a mitral regurgitation model but not in a heart failure model, (39) and in atrial ischemia, but not in an atrial tachycardia model. (40) Atrial dilatation may activate certain ion channels, and blockade of these channels by stretch activated channel blockers might be The Na-Ca exchange mechanism on myocyte membranes normally moves 3 molecules of Na into the cell for every one molecule of Ca moving out of the cell. In rapid atrial pacing or fi brillation, this exchange is reversed. Inhibitors of Na-Ca exchange prevent this reversal. An example is KB-R7943 which blocks a number of other channels also.
Ranolazine is a piperazine derivative with anti-anginal / anti-ischemic properties and was investigated in the MERLIN-TIMI 36 trial where it was shown to signifi cantly reduce unsustained ventricular tachycardia and supra-ventricular tachycardia incidence, and it also reduced the incidence of new AF, albeit not signifi cantly (1.7% vs. 2.4%, P=0.08). (41) Ranolazine uniquely is an inhibitor of the late phase of the inward sodium current (late I Na ) but is also a blocker of multiple other channels including peak I Na , I Kr , I Ks , I CaL and Na-Ca exchange. It causes minimal QTc prolongation (2-6mS).
CONCLUSION
Although a strategy of ventricular rate control may not be inferior to rhythm control in some patients with AF, drug treatment for rhythm control is likely to increase in the future as a result both of the increasing incidence of atrial fi brillation as well as the development of exciting new drugs which will not have adverse effects, especially pro-arrhythmia.
Advances in ablation techniques for AF will have an impact only on a small segment of the patient population. Hopefully new anti-coagulants will be unburdened from the need for frequent laboratory testing in the future.
